{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jia X"],"funding":["Central Plains science and technology innovation leading talents","National Natural Science Foundation of China","Science and Technology project of Henan Province"],"pagination":["97"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10124032"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(1)"],"pubmed_abstract":["<h4>Background</h4>Although molecular targets such as HER2, TP53 and PIK3CA have been widely studied in esophageal cancer, few of them were successfully applied for clinical treatment. Therefore, it is urgent to discover novel actionable targets and inhibitors. Eukaryotic translational elongation factor 2 (eEF2) is reported to be highly expressed in various cancers. However, its contribution to the maintenance and progression of cancer has not been fully clarified.<h4>Methods</h4>In the present study, we utilized tissue array to evaluate eEF2 protein expression and clinical significance in esophageal squamous cell carcinoma (ESCC). Next, we performed knockdown, overexpression, RNA-binding protein immunoprecipitation (RIP) sequence, and nascent protein synthesis assays to explore the molecu"],"journal":["Journal of experimental & clinical cancer research : CR"],"pubmed_title":["Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth."],"pmcid":["PMC10124032"],"funding_grant_id":["222102310029","81872335","82073075","224200510015"],"pubmed_authors":["Li H","Huang C","Liu K","Wu Q","Dong Z","Li P","Huang L","Laster KV","Lu B","Jiang Y","Li X","Wang P","Tian X","Jia X","Zhao D","Nie W"],"additional_accession":[]},"is_claimable":false,"name":"Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth.","description":"<h4>Background</h4>Although molecular targets such as HER2, TP53 and PIK3CA have been widely studied in esophageal cancer, few of them were successfully applied for clinical treatment. Therefore, it is urgent to discover novel actionable targets and inhibitors. Eukaryotic translational elongation factor 2 (eEF2) is reported to be highly expressed in various cancers. However, its contribution to the maintenance and progression of cancer has not been fully clarified.<h4>Methods</h4>In the present study, we utilized tissue array to evaluate eEF2 protein expression and clinical significance in esophageal squamous cell carcinoma (ESCC). Next, we performed knockdown, overexpression, RNA-binding protein immunoprecipitation (RIP) sequence, and nascent protein synthesis assays to explore the molecu","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-07-15T01:27:56.814Z","creation":"2025-02-19T02:57:04.022Z"},"accession":"S-EPMC10124032","cross_references":{"pubmed":["37088855"],"doi":["10.1186/s13046-023-02666-5"]}}